Ruzicka Marcel, Edwards Cedric, McCormick Brendan, Hiremath Swapnil
Division of Nephrology, The Ottawa Hospital and University of Ottawa, 1967 Riverside Drive, Ottawa, ON, Canada.
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada.
Curr Treat Options Cardiovasc Med. 2017 Sep 14;19(10):80. doi: 10.1007/s11936-017-0577-8.
Intensive blood pressure lowering to systolic blood pressure thresholds of less than 120 mmHg is making a slow comeback with the publication of trials supporting its benefit, especially in lowering stroke and congestive heart failure. At the same time, there is an increasing awareness of the prevalence and risk of diastolic hypotension, especially at levels of less than 60 mmHg, with support for the existence of a J-curve coming from post hoc analyses of trials and epidemiological data from large cohort studies. Hence, intensive lowering of systolic blood pressure should be done cautiously in those patients who have pre-existing coronary artery disease, and a diastolic blood pressure between 60 and 70 mmHg. Among those with diastolic blood pressure already below 60 mmHg, but whose systolic blood pressure is not at target, we recommend shared decision-making with an explicit discussion of the risks and benefits, and taking patient preferences into account. Further research with biomarkers and risk models exploring heterogeneity of outcomes might allow for more precise targeting of intensive blood pressure lowering in individuals most likely to benefit, with avoiding those most likely to harm.
随着支持收缩压降至低于120mmHg阈值有益的试验发表,强化降压正慢慢卷土重来,尤其是在降低中风和充血性心力衰竭方面。与此同时,人们越来越意识到舒张期低血压的患病率和风险,特别是在低于60mmHg的水平,对J曲线存在的支持来自试验的事后分析和大型队列研究的流行病学数据。因此,对于已有冠状动脉疾病且舒张压在60至70mmHg之间的患者,应谨慎进行强化收缩压降低。在舒张压已低于60mmHg但收缩压未达目标的患者中,我们建议进行共同决策,明确讨论风险和益处,并考虑患者偏好。利用生物标志物和风险模型对结局异质性进行进一步研究,可能有助于更精准地针对最可能受益的个体进行强化降压,同时避免对最可能受伤害的个体进行强化降压。